Pharmaceutical News

Global Biopharma Layoffs October 2026 Layoffs Caribou Biosciences GSK Enlivex Global biopharma layoffs in October 2026 include workforce cuts and shutdowns at Adecto Pharmaceuticals, Aviceda Therapeutics, and Foghorn Therapeutics following pipeline setbacks and strategic restructuring.
Evonik Cuts 3,200 Jobs as Growth Strategy Sharpens Evonik Layoffs Layoff Evonik will cut 3,200 jobs worldwide while reshaping its portfolio, consolidating German sites and investing in growth markets across Asia and the Americas under its Tailor Made restructuring program.
Pfizer, Lilly MFN Deals Reshape Global Drug Pricing | GuideView Pfizer Eli Lilly Pfizer and Eli Lilly’s MFN drug-pricing deals reveal revenue-sharing provisions tied to higher foreign prices. GuideView examines the agreements, industry impact, global pricing strategy, and remaining transparency concerns.
ART27.13 Shows Strong Weight-Loss Potential in Obese Mice GLP-1 Semaglutide Weight loss Artelo’s ART27.13 matched semaglutide for weight loss in obese mice and doubled weight reduction when combined with it, highlighting a potential new cannabinoid-based approach to weight management.
Telix Acquires ITM for $1.65B, Expanding Radiopharma Reach Telix Market Trend Telix acquires ITM Isotope Technologies Munich for $1.65B, expanding its radiopharmaceutical pipeline and manufacturing network. The deal advances ITM-11 while strengthening Telix’s position in radioligand therapy.
Inluriyo-Verzenio FDA Approval Reshapes Oral SERD Market Eli Lilly FDA AstraZeneca Eli Lilly’s Inluriyo-Verzenio gains FDA approval for ESR1-mutated breast cancer, intensifying oral SERD competition and shifting the market toward combination therapy, earlier intervention, and adjuvant treatment.
Global Biopharma Layoffs September 2026 Layoffs Layoff Cellares Arsenal Biosciences Novartis GSK Global biopharma layoffs in September 2026 include major workforce cuts at GSK, Sionna Therapeutics, Merck, TScan Therapeutics, Novartis, Arsenal Biosciences and Cellares amid restructuring and cost reductions.
Global Biopharma Layoffs August 2026 Layoffs Layoff Lisata Therapeutics Pfizer Ensoma Sanofi Biotech layoffs are accelerating across the industry, with workforce cuts, restructuring and program shutdowns affecting companies including EMD Serono, Blueprint Medicines, Aardvark, Aura, aTyr and others.
Global Biopharma Layoffs July 2026 Layoffs Layoff BioNTech Genentech Novartis Amgen Genentech is cutting 103 jobs at its South San Francisco headquarters amid targeted restructuring, while BioNTech plans major site closures affecting about 2,000 positions as it shifts focus toward oncology and streamlines global operations.
Global Biopharma Layoffs June 2026 Layoffs Layoff Merck Genentech Fulcrum Therapeutics is cutting 85% of its workforce after discontinuing its lead sickle cell drug program, as it restructures to conserve cash and reduce operating expenses following regulatory setbacks. And Merck is laying off 88 employees in Rahway, New Jersey.